Brefeldin A and Cytochalasin B reduce dengue virus replication in cell cultures but do not protect mice against viral challenge

Kleber Juvenal Silva Farias¹,²*, Paula Renata Lima Machado³, Renato Ferreira de Almeida Júnior³ and Benedito Antônio Lopes da Fonseca¹

INTRODUCTION
There are a large number of viruses in the family Flaviviridae that are common in nature. These are responsible for causing serious diseases in humans and animals. The family is composed of three genera: Flavivirus, Pestivirus and Hepacivirus. The flavivirus genus contains more than 70 viruses transmitted by arthropods, including dengue virus (DENV), Japanese encephalitis virus, tick-borne encephalitis virus, West Nile virus and yellow fever virus, and are considered emerging and re-emerging pathogens. Within each genus, viruses can be subdivided into antigenic complexes [1, 2].

Dengue viruses are members of the family Flaviviridae and classified epidemiologically as arboviruses. There are four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3 and DENV-4) and all can cause both the classical form of the disease and dengue haemorrhagic fever. Virulence is directly proportional to the intensity with which the virus multiplies in the body. Human target cells for dengue virus replication are those belonging to the monocyte–macrophage lineage [3].

DENV is mainly transmitted by Aedes aegypti. Only the female mosquito transmits the disease, as it seeks blood as food during the development of its eggs [4].

The dengue virion is a spherical particle, approximately 50 nm in diameter and consists of an icosahedral nucleocapsid and envelope [5]. The viral capsid involves a central nucleus of RNA forming the nucleocapsid. The envelope originates from the inner membrane of the endoplasmic reticulum (ER), when the viral particles arise from the lumen of the ER to the cytoplasm [6].

DENV is an enveloped, positive, ssRNA virus with genome of approximately 11 kb containing a single ORF. The ORF is
processed by virally encoded protease (NS2B and NS3) to generate individual proteins: three structural proteins, capsid (C), pre-membrane/membrane (PrM/M) and envelope (E), and seven non-structural (NS) proteins, NS1, NS2A/2B, NS3, NS4A/4B and NS5, flanked by 5'- and 3'-non-translated regions (5NTR/3NTR). The structural proteins form the viral particle while the non-structural proteins participate in replication and invasion of the immune system [5, 7].

Dengue viruses are transmitted to humans by Aedes aegypti or Aedes albopictus mosquitoes. The virus can replicate in mononuclear cells (monocytes, macrophages and dendritic cells), in specific organs such as spleen, liver, lymph node, kidney and other organs [8]. Dengue viruses enter into the host cell by receptor-mediated endocytosis and replicate in the cytoplasm after 12–16 h of infection. The receptor molecules on the surface of the target cell that the DENV binds to in the initial phase of infection are unknown, although evidence suggests that heparan sulfate is an active participant at this stage of infection [9, 10]. After penetration into the cytoplasm, dissociation of E homodimers takes place as a result of the acidic environment in the endosome, resulting in fusion of the viral envelope with the endosomal membrane. After fusion has occurred, the nucleocapsid is released into the cytoplasm, where the capsid proteins and the RNA dissociate, initiating replication of the genomic uncoating RNA and assembly of the viral particle [7]. Viral RNA replicates in perinuclear areas, mediated by a negative-polar RNA that serves as a template for virus RNA replication. The viral RNA is translated into a single polyprotein that is cleaved co- and post-translationally by cellular and virus-derived proteases into three structural proteins and seven NS proteins [11]. The translation of RNA occurs in the ER. The NS proteins initiate viral genome replication at the intracellular membranes, resulting in the production of more viral RNA strands [12, 13]. Newly synthesized RNA is packed by C proteins to form the nucleocapsid. Non-infectious immature viral particles formed contain the glycoproteins E and prM, lipid membrane and nucleocapsid. Immature viral particles are transported to the Golgi complex where cleavage of prM by the furin (host protease) occurs by removal of the glycine portion of this protein, resulting in mature viral particles being released from the host cell by exocytosis of the actin filaments [14].

There are no antiviral DENV drugs available at present; supportive treatment focuses on fluid therapy and close clinical monitoring during the critical phase of dengue disease.

RNA viruses, like DENV, alter cellular membranes during their replication, and viral RNA synthesis occurs in membranous vesicles produced by the ER. During replication, viral capsid protein is responsible for recruitment of the viral genome during encapsidation, forming a nucleocapsid that springs into the ER lumen, acquiring membranes and the structural proteins E and prM [15]. The new viral particle migrates through the secretory pathway to be released by exocytosis. Brefeldin A (BFA) inhibits secretion and morphological changes in other organelles, leading to a dissociation of the Golgi complex, preventing the secretion of lipid vesicles [16, 17]. Previous studies with BFA have shown that lipid-containing viruses which mature along the secretory pathway are modified by BFA [18–20].

Studies by Mirazimi et al. [21] showed for the first time also viruses which assemble and remain in the ER are affected by BFA, which reduced progeny virus yield by 99%. The BFA was used in a study by Iglesias et al. [22] in which they observed that this drug inhibited the high titre of dengue virus. Experiments with BFA showed that the virus needs the traffic vesicular of proteins for their replication, therefore the presence of the drug provoked an effect inhibitor in the replicative cycle of the Kunjin virus [23], as well as for the West Nile virus in Vero cells [24]. The inhibitory effect of BFA on virus replication in mammalian cells has already been studied with other viruses, such as human immunodeficiency virus (HIV-1), and the rubella virus [15, 25]. In the study realized by Tamura et al. [26] showed that BFA inhibited the replication of vaccinia virus and Newcastle disease virus. Study using BFA against encephalomyocarditis virus, demonstrated that BFA antagonized the antiviral action of IFN by inhibiting IFN-induced enzymatic pathways [27].

The actin cytoskeleton is an important structure responsible for transport in cells, but it has a key role in stages of viral replication such as maturation and release. The actin cytoskeleton is also critical for clathrin-coated structure that is fundamental for flaviviruses that enter mammalian and mosquito cells by clathrin-dependent endocytosis [28]. Chu et al. [29] showed for the first time that actin filaments directly participated in the budding of West Nile virus at the plasma membrane. Perturbation of actin filaments by Cytochalasin B (CB) strongly inhibited the release of West Nile virus (~10 000-fold inhibition). Boulanger et al. [30] have also postulated that the disruption of actin filaments by cytochalasin could disengage the interaction between actin and its membrane linker, destabilizing the interaction between fowlpox virus precursors and the plasma membrane, and the virus yield was reduced. Bohn et al. [31] showed that measles virus-infected HeLa cells treated with CB had a reduced viral yield. Studies using cytochalasin D (CD) have also shown significant results: Wang et al. [32], when treating ECV304 cells infected with DENV-2 with CD, reported a reduction of the viral titres in the first hours of infection, again demonstrating that actin filament disturbance blocks viral release. Acosta et al. [33], studying CD on DENV-2-infected C6/36 cells, observed that the drug significantly reduced viral titres when cells were pretreated. Mosso et al. [34] also found that CD inhibited DENV infection by more than 80% in C6/36 cells in treatment situations before or after infection. However, CB antiviral activity against Sindbis and vesicular stomatitis virus was not observed by Coombs et al. [35]. Griffins and Compans [36] noted that CB inhibited viral replication, but did not reduce the infectivity of influenza viruses or vesicular stomatitis viruses. BFA (Fig. 1a) and CB (Fig. 1b) exhibit various in vitro and in vivo biological actions, including antitumour, antifungal and antiviral activities with different mechanisms of action.
[26, 27, 35–37]. BFA, a unique fungal metabolite of a 13-membered lactone ring, blocks the secretion of proteins by dissociation of the Golgi apparatus, and CB, a mycogenic toxin known to disrupt the formation of actin polymers, destabilizes the cytoskeleton thus impeding the process of synthesis of cellular proteins [38, 39].

Thus, the aim of this study was to examine the in vitro and in vivo effects of BFA and CB on DENV-2 replication in DENV-2-infected Vero cells and DENV-2-infected mice, respectively. The results suggest that BFA and CB could be potential therapeutic agents to combat dengue infection.

METHODS

Ethics statement

This study was carried out in strict accordance with the Brazilian Government's ethical and animal experiment regulations. The procedures using animals in this research project were specified in accordance with the ethical principles established by the Brazilian College of Animal Experimentation (COBEA), and the experimental protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Sao Paulo (CETEA/USP, Permit Protocol Number 080/2006). All surgical procedures were performed under ketamine/xylazine anaesthesia, and all efforts were made to minimize animal suffering.

Cell cultures

Vero cells (continuous cell lineage originating from the kidney of African green monkeys) were grown in Leibovitz-15 (L-15) culture medium (Invitrogen) supplemented with 10% FBS, 1% L-glutamine 200 mM, 1% penicillin G (100 U ml⁻¹) and streptomycin (100 µg ml⁻¹). Vero cells were maintained at 37 °C. C6/36, an Aedes albopictus cell line, was cultured in L-15 medium supplemented with 10% FBS, L-glutamine, 1% penicillin G (100 U ml⁻¹), and streptomycin (100 µg ml⁻¹), at 28 °C.

Virus stock

The parental DENV-2 New Guinea C strain used in this study was recovered from brains of intracerebrally infected 1- to 2-day-old suckling Swiss mice in the Virology Research Center, University of Sao Paulo, Ribeirao Preto, Brazil. The animals were killed, and the brains were removed in a sterile environment. Each brain was homogenized in 900 µl of bovine skin gelatin 4% (Sigma Aldrich). The infected brain fluid (IBF) was centrifuged at 2800 g for 20 min at 4 °C. After centrifugation, the IBF was kept in ice to prevent further microbial loss, and then divided into aliquots and stored frozen at −80 °C. Virus stock supernatant fluid used in the present study was free of lipopolysaccharides and mycoplasmas.

Dengue virus titration

Virus production was titrated by a plaque assay using Vero cells, as described by Russell and Nisalak [40]. Vero cells were seeded in a 12-well plate (6×10⁵ cells per well) in L-15 medium with 10% FBS for 48 h at 37 °C. The medium was removed, and decimal serial dilutions of virus stock were added (0.1 ml per well) to the cells, which were then incubated for 2 h at 37 °C. Subsequently, L-15 medium containing 5% FBS and 3% carboxymethyl-cellulose (1 ml per well; overlay) was added, and the plate was incubated at 37 °C for 7 days. The overlay was removed on day 7, and cells were fixed with a solution of 10% formaldehyde in PBS. After 2 h at room temperature, the formaldehyde solution was removed, and cells were washed twice with PBS and stained (15 min) with a 1% crystal violet solution in 20% ethanol. The plaques of cell lysis were counted, and the virus concentration was expressed as plaque-forming units (p.f.u.) per millilitre.
Preparation of antiviral solutions

Antiviral solutions were prepared as follows: BFA was solubilized in ethanol (Santa Cruz Technology) at a concentration of $18 \times 10^3 \mu M$ ($0.005 \text{g/ml}$ ethanol) and CB was solubilized in DMSO (Sigma) at a concentration of $2 \times 10^3 \mu M$ ($0.001 \text{g/ml}$ DMSO). The DMSO or ethanol was injected through the rubber stopper of the vial to attain a final concentration of CB of $5 \text{mg/ml}$ and BFA of $1 \text{mg/ml}$, respectively. The drug suspensions were shaken until full dissolution. Stock solutions were stored at $-20^\circ C$. The drugs were diluted in L-15 medium to prepare working stock solutions immediately before use.

Cytotoxicity test: MTT assay

To evaluate the cytotoxicity effect of the drugs (BFA and CB) and organic solvents (ethanol and DMSO) on the Vero cells, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay [41], which has been widely used and validated, was applied. The MTT was provided by Sigma-Aldrich. Vero cells were seeded in 96-well plates ($1 \times 10^4$ cells per well) and exposed to different concentrations of BFA ($0, 0.05, 0.5, 5, 50$ and $500 \mu g/m^3$), CB ($0, 0.01, 0.1, 1, 10, 100$ and $1000 \mu g/m^3$), ethanol ($10, 5, 2.5, 1.2, 0.62, 0.31$ and $0.15 \%, \text{v/v}$) and DMSO ($10, 5, 2.5, 1.2, 0.62, 0.31$ and $0.15 \%, \text{v/v}$); all compounds were diluted in L-15 medium. After treatment, the plates were incubated at $37^\circ C$. A duration of 168 h was chosen for determining cytotoxicity in vitro. The assay was performed with the drugs added either only once or at 24 h intervals. After incubation, the supernatant was removed and $50 \mu l$ of L-15 containing MTT ($1 \text{mg/ml}$) was added to each well. After 4 h of incubation at $37^\circ C$, the supernatant was removed and $100 \mu l$ DMSO was added to each well to solubilize the formazan crystals. After shaking the plate, absorbance values obtained from cells treated with drugs, ethanol and DMSO were measured at $540 \text{nm}$. Cell survival was determined by comparison between the absorbance values obtained from cells treated with drugs, ethanol and DMSO with untreated cells [41]. The percentage cytotoxicity of each dilution was calculated as $(A/B) \times 100$, where $A$ is the absorbance values from each treated well and $B$ is the average of the controls. Viability was established from the average of triplicate determinations for each dilution. The 50% cytotoxic concentration ($CC_{50}$) was defined as the sample concentration that reduced cell viability by 50% when compared to untreated controls. The 50% inhibitor drug concentration of the viral effect ($IC_{50}$) was derived from concentration–effect curves after linear regression analysis. The selective index (SI) was defined as the ratio of $CC_{50}$ to $IC_{50}$.

The calculation of the $IC_{50}$ was performed under the conditions and concentrations described below.
Time-of-addition studies

Monolayers of Vero cells seeded onto 24-well plates were infected with DENV-2 at an m.o.i. of 0.1. Time-of-addition studies were performed as follows. After-infection assay: after virus adsorption and washing, BFA (0, 0.05, 0.5 and 5 µg ml⁻¹) or 1% ethanol (control), CB (0, 0.01, 0.1, 1 and 10 µg ml⁻¹) or 0.1% DMSO (control) were added at different time points post-infection (pi) as follows: (i) 1 h after infection; (ii) 1 h after infection and at 24 h intervals for 7 days. DENV-2 replication of mock control was 0 µg ml⁻¹. Infected cell supernatants were harvested at 0, 6, 12, 24, 48, 72, 96, 120, 144 and 168 h pi. Virus replication was monitored by quantitative real-time PCR and plaque assays. Each concentration of the drug was assayed in triplicate and repeated in two independent experiments and the results are shown as the mean values obtained from these experiments.

Viral RNA extraction

RNA was extracted from 140 µl of each supernatant sample using the QIAamp Viral RNA kit (Qiagen) according to the manufacturer's directions.

Real-time quantitative reverse transcription PCR (qRT-PCR) assay

In order to construct standard curves, the number of DENV-2 particles produced by infected cells was measured as the number of RNA copies quantified by qRT-PCR in serially diluted infected cell supernatants, after clearing by centrifugation. Each qRT-PCR contained 12.5 µl of the SYBR Green Master Mix reagent (Applied Biosystems), 0.5 µl RNase inhibitor, 0.13 µl Multiscribe (50 U µl⁻¹), 0.5 µl primers (20 nM) DV2U (F 5'-AAGGTGAGATGAAGCTGTAGTCTC-3') and DVL1 (R 5'-CATTCATTCTTCTGGCGTTCT-3') specifically designed to anneal to the DENV-2 3'-untranslated region (3'-UTR), 5.87 µl diethyl pyrocarbonate (DEPC) water, and 5 µl RNA to a final volume of 25 µl [42]. The amplification protocol consisted of the following steps: 48 °C for 30 min and 95 °C for 10 min, followed by amplification with 40 cycles at 95 °C for 15 s and 60 °C for 1 min. The same protocol was used to quantify the DENV-2 RNA copies present in the supernatants of CB- or BFA-treated and untreated Vero cells infected with DENV-2, collected at defined post-infection intervals, as described above.

Post-challenge protection

Forty 6-week-old females of wild-type young adult Swiss mice were infected intracerebrally with a dose of 100× LD₅₀ (previously determined) of a neurovirulent DENV-2 in a volume of 100 litres (3×10⁵ p.f.u.) [43]. The protection of drugs was evaluated for 21 days. The animals used in the experiment were randomly divided into eight groups of five animals each. Thus, four groups were infected with DENV-2, and after 2 h two groups received either a single intraperitoneal (i.p.) dose of BFA (26.3 mg kg⁻¹) [44] or CB (1.2 mg kg⁻¹) [45]. Two groups received only PBS (mock) i.p. The other two groups received a single i.p. inoculum of either BFA or CB (negative control). Survival analysis was performed by observing these animals for the appearance of
signs of disease such as tremors, hind limb paralysis, ruffled pile, muscle weakness and difficulty feeding. All mice were maintained under specific pathogen-free conditions.

The half-life of the drugs is short, which, after their i.p. or intravenous administration, are distributed in various organs within 15–180 min for CB and 60 min for BFA followed by a gradual reduction until their complete elimination after 24 h [46].

**Statistical analysis**

Statistical analysis was used to assess the difference in viral yield, at time-defined intervals, by infected cells in contact with BFA or CB compared to control cells (without the drugs). Data were entered into the GraphPad Prism software, version 6.0 (GraphPad Software). In this study, our data are non-parametric and have two independent variables (time and treatment), so we used two-way ANOVA statistical tests followed by multiple Kruskal–Wallis comparisons. For all analyses, values of P<0.05 were considered statistically significant.

**RESULTS**

**Cytotoxicity of drugs in Vero cells**

Concentrations equal to or higher than 50 µg ml⁻¹ (BFA) and 100 µg ml⁻¹ (CB) were highly cytotoxic to Vero cells, while concentrations equal to or lower than 5 µg ml⁻¹ (BFA) and 10 µg ml⁻¹ (CB) did not induce significant cytotoxicity. Based on these data, concentrations equal to or lower than 5 µg ml⁻¹ (BFA) and 10 µg ml⁻¹ (CB) were used in the experiments (Fig. 2a, b). The final concentration of ethanol and DMSO in the antiviral solution stock of BFA and CB was 0.5 and 0.1%, respectively. These concentrations were not cytotoxic to Vero cells. (Fig. 2c).

The CC₅₀ values were 31.3 µg ml⁻¹ for BFA and 43.5 µg ml⁻¹ for CB.

**Effect of drugs on DENV-2 replication**

To determine whether BFA would inhibit DENV-2 replication, monolayers of Vero cells were infected with DENV-2 and incubated with 2% FBS L-15 medium containing varying doses of BFA or CB. These drugs proved to be potent inhibitors of DENV-2, exhibiting antiviral activity, showing a dose-dependent inhibition of viral yields. Virus production by infected cells was detected by qRT-PCR using the standard curve to measure viral load and the results showed that BFA and CB reduced DENV-2 replication in Vero cells. Viral replication was inhibited by the addition of BFA at ≤5 µg ml⁻¹ or CB at ≤10 µg ml⁻¹ 1 h after infection when compared to untreated cells up to the first day after infection (Fig. 3a, b). Dilution (0.1 µg ml⁻¹) of CB elicited partial inhibition (Fig. 3b). Further dilution (0.05 µg ml⁻¹) of BFA or (0.01 µg ml⁻¹) CB caused viral inhibition to disappear (Fig. 3a, b). The same results were obtained with the plaque assays; there was an excellent correlation between the plaque assays and the viral load determined by qRT-PCR (Fig. 3c, d).

In an attempt to further improve inhibition of viral replication, BFA or CB was added 1 h after infection and at 24 h intervals after infection. The time-of-addition of the drugs after 1 h of infection and at 24 h intervals did not show differences in relation to when the drugs were applied only once (data not shown). When the number of viral RNA copies of DENV-2

---

**Fig. 4.** Action of BFA or CB, added at 24 h intervals, on DENV-2 replication in Vero cells. (a,b) The viral RNA present in the culture supernatants of Vero cells infected with DENV-2, treated or untreated with BFA or CB 1 h post-infection, and at 24 h intervals, was extracted and analysed by qRT-PCR. (c,d) Culture supernatants of Vero cells infected with DENV-2, treated or untreated with BFA or CB 1 h post-infection, and at 24 h intervals, were analysed by plaque assay. The results represent the average values of the viral RNA copy number (P<0.001). BFA, brefeldin A; CB, cytochalasin B; DENV-2, dengue-2 virus; qRT-PCR, real time quantitative reverse transcriptase PCR.
was assayed in supernatants of Vero-infected cells treated with BFA or CB, we observed a reduction in viral yield compared to untreated cells (0 µg ml⁻¹) up to the seventh day after infection (Fig. 4a, b). With this approach, both the plaque assay and qRT-PCR showed a statistically significant reduction in viral yield similar to that obtained for cells exposed to BFA or CB at 1 h after infection (Fig. 4c, d). We concluded that an appropriate amount of BFA or CB could inhibit DENV-2 replication without affecting cell viability.

The IC₅₀ values were 2.72 µg ml⁻¹ for BFA and 6.72 µg ml⁻¹ for CB.

**Protection post-challenge**

All mice survived when only injected with drugs or PBS, while the animals that were inoculated with DENV-2 died on the 10th day after challenge. The groups of mice that received BFA or CB 2 h after viral infection showed 40% survival on day 10, but all mice had died by day 11 (Fig. 5a, b).

**DISCUSSION**

Our results showed that BFA and CB reduced viral replication when the cells were treated at intervals of 24 h over 7 days of incubation.

Raekiansyah et al. [47] characterized an anti-DENV agent of fungus-derived BFA which can potentially be used as a lead compound for drug development of anti-DENV and other related viruses. To evaluate the antiviral activity of a sample in this study, Vero cells were infected and treated with BFA and incubated for 24 h when infected culture fluid (ICF) was harvested for virus quantification. In our study, the kinetics of ICF treated using both single dosing and multiple daily dosing of BFA for a period of 7 days showed good results when compared to single dosing. The study of Raekiansyah et al. [47] may have treated cultures of infected cells with multiple daily dosing for a extended period of time, and thus obtained better results.

In our in vivo experiments, the groups that received BFA or CB did not show satisfactory results, with percentage survival of DENV-2-infected mice treated or not with the drugs being similar.

The mechanism of disruption of vesicular transport between the ER and Golgi by BFA and destabilization of actin filaments by CB are critical steps for viral replication and release, and could provide a new tool to characterize the lifecycle of the virus. These drugs can also help researchers explore strategies for the development of DENV inhibitors. Furthermore, their antiviral activity can also be improved through derivative analyses or other approaches.

These results suggest that BFA inhibits DENV at an early phase in the viral replication cycle after viral entry. Our study proposes that BFA and CB are potential antiviral candidates against DENV-2 in culture cell. We speculate that BFA inhibits enveloped viruses, by blocking the trafficking of glycoprotein from the ER to Golgi, preventing the formation of new viruses, and that CB destabilizes actin filaments, thereby interfering with virus assembly and reducing the infection.

**Funding information**

This study was supported by FAPESP (Sao Paulo Foundation for Research), (Grant# 05/04450–4). K. J. S. F was supported by a FAPESP fellowship (Grant# 04/03635–8).

**Conflicts of interest**

The authors declare that there are no conflicts of interest.

**References**

1. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. Phylogeny of the genus flavivirus. J Virol 1998;72:73–83.

2. Lindenbach BD, Rice CM. Fields Virology. In: Knipe DM and Howley PM (editors). Flaviviridae Replication, 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 991–1041.

3. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988;239:476–481.

4. Fonseca BAL, Figueiredo LTM, Em D. Dengue. In: Focaccia Roberto (editor). Em “Tratado de infectologia”, 3ª edição; 2005. pp. 343–356.

5. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002;108:717–725.

6. Guirakhoo F, Heinz FX, Mandi CW, Holzmann H, Kunz C. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis viroms. J Gen Virol 1991;72:1323–1329.

7. Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv Virus Res 2003;59:23–61.
8. Richman DD, Whitley RJ, Hayden FG. Flaviviruses. Clinical Virology. 2nd edition. Washington, D.C.: 2002. pp. 1103–1104.

9. Swaminathan S, Khanna N. Dengue: recent advances in biology and current status of translational research. Curr Mol Med 2009;9:152–173.

10. Huerta V, Chinea G, Fleitas N, Sarria M, Sánchez J et al. Characterization of the interaction domain of III of the envelope protein of dengue virus with putative receptors from CHO cells. Virus Res 2008;137:225–234.

11. Rice CM, Lenches EM, Eddy SR, Shin SJ. Sheets RL et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985;229:726–733.

12. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990;44:649–688.

13. Uchil PD, Satchidanandam V. Architecture of the flaviviral replication complex. J Biol Chem 2003;278:24388–24398.

14. Elshuber S, Allison SL, Heinz FX. Mandl CW. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen Virology 2003;84:183–191.

15. Qiu Z, Tufaro F, Gillam S. Brefeldin A and monensin arrest cell surface expression of membrane glycoproteins and release of rubella virus. J Gen Virol 1995;76:855–863.

16. Lippincott-Schwartz J, Yuan L, Tipper C, Amherdt M, Orci L et al. Brefeldin A effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic. Cell 1991;67:601–616.

17. Pelham HRB. Multiple targets for brefeldin A. Cell 1991;67:449–451.

18. Doms RW, Russ G, Yewdell JW. Brefeldin A redistributes resident and itinerant Golgi proteins to the endoplasmic reticulum. J Cell Biol 1989;109:61–72.

19. Chen SY, Matsuoka Y, Comps RW. Assembly and polarized release of punta toro virus and effects of brefeldin A. J Virol 1991;64:1427–1439.

20. Weclewicz K, Kristensson K, Greenberg HB, Svensson L. The endoplasmic reticulum-associated VP7 of rotavirus is targeted to axons and dendrites in polarized neurons. J Neurocytol 1993;22:616–626.

21. Mirazimi AJ, Bonsdorff CV, Svensson L. Effect of Brefeldin A on Rotavirus Assembly and Oligosaccharide Processing. Virology 1996;217:554–563.

22. Iglesias NG, Mondotte JA, Byk LA, De Maio FA, Samsa MM et al. Dengue virus uses a non-canonical function of the host GFB1-1-Art-COPI system for capsid protein accumulation on lipid droplets. Traffic 2015;16:962–977.

23. Mackenzie JM, Westaway EG. Assembly and maturation of the Flavivirus kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 2001;75:10787–10799.

24. Sreenivasan V, Ng KL, Ng ML, ML N. Brefeldin A affects West Nile virus replication in Vero cells but not C6/36 cells. J Virol Methods 1993;45:1–17.

25. Bernstein HB, Comps RW. Sulphation of the human immunodeficiency virus envelope glycoprotein. J Virol 1992;66:6953–6959.

26. Tamura G, Ando K, Suzuki S, Takatsuki A, Arima K. Antiviral activity of brefeldin A and verrucarin a. J Antimicrob Chemother 1968;21:160–161.

27. Sidhu GS, Singh AK, Raghunath PN, Sivaram S, Maheshwari RK. Brefeldin A inhibits the antiviral action of interferon against encephalomyocarditis virus. Virus Res 1996;40:123–133.

28. Cooper JA. Effects of cytochalasin and phalloidin on actin. J Cell Biol 1987;105:1473–1478.

29. Chu JJH, Choo BGH, Lee JWM, Ng ML, NL N. Actin filaments participate in West Nile (Sarafend) virus maturation process. J Med Virol 2003;71:463–472.

30. Boulanger D, Skinner MA, Smith T. Morphogenesis and release of fowlpox virus. J Gen Virol 2000;81:675–687.

31. Bohn W, Rutter G, Hohenberg H, Mannweiler K, Nobis P. Involvement of actin filaments in budding of measles virus: studies on cytoskeletons of infected cells. Virology 1986;149:91–106.

32. Wang JL, Zhang JL, Chen W, Xu XF, Gao N et al. Roles of small GTPase Rac1 in the regulation of actin cytoskeleton during dengue virus infection. PLoS Negl Trop Dis 2010;4:e809.

33. Acosta EG, Castilla V, Damonte EB. Functional entry of dengue virus into Aedes albopictus mosquito cells is dependent on clathrin-mediated endocytosis. J Gen Virol 2008;89:474–484.

34. Mosso C, Galván-Mendoza IJ, Ludert JE, del Angel RM. Endocytic pathway followed by dengue virus to infect the mosquito cell line C6/36 HT. Virology 2008;378:193–199.

35. Coombs K, Mann E, Edwards J, Brown DT. Effects of chloroquine and cytochalasin B on the infection of cells by Sindbis virus and vesicular stomatitis virus. J Virol 1981;37:1060–1065.

36. Griffin JA, Comps RW. Effect of cytochalasin B on the maturation of enveloped viruses. J Exp Med 1979;150:379–391.

37. Trendowski M, Mitchell JM, Corsette CM, Acquafoodata C, Fondy TP. Chemotherapy with cytochalasin congenerers in vitro and in vivo against murine models. Invest New Drugs 2015;33:290–299.

38. Ghosh S, Ahrens WA, Phatak SU, Hwang S, Schrum LW et al. Association of filament A and vimentin with hepatitis C virus proteins in infected human hepatocytes. J Viral Hepat 2011;18:e568–e577.

39. Grose C, Klonsky DJ. Alternative autophagy, brefeldin A and viral trafficking pathways. Autophagy 2016;12:1429–1430.

40. Russell PK, Nisalak A. Dengue virus identification by plaque reduction neutralization test. J Immunol 1967;99–291.

41. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.

42. Houng HSH, Chung-Ming Chen R, Vaughn DW, Kanesha-thasan N. Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1–4 using conserved and serotype-specific 3’ noncoding sequences. J Virol Methods 2001;95:19–32.

43. Trevan JW. The error of determination of toxicity. Proceedings of the Royal Society B: Biological Sciences 1927;101:483–514.

44. Phillips LR, Supko JG, Malspeis L. Analysis of Brefeldin A in Plasma by Gas Chromatography with Electron Capture Detection. Anal Biochem 1993;211:16–22.

45. Austin WL, Wind M, Brown Chromatography with Electron Capture Detection. Anal Biochem 1993;211:16–22.

46. Anwyl R, Narahashi T. Action of colchicine and cytochalasin B on the acetylcholine receptor. Br J Pharmacol 1979;65:483–488.

47. Raekiansyah M, Mori M, Nonaka K, Aghoh M, Shiomi K et al. Identification of novel antiviral of fungus-derived brefeldin A against dengue viruses. Trop Med Health 2017;45:32.